{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:48:31Z","timestamp":1782254911987,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00384-007-0395-7","type":"journal-article","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T08:28:37Z","timestamp":1197275317000},"page":"289-296","source":"Crossref","is-referenced-by-count":45,"title":["Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF\u03b1, improves health-related quality of life in patients with moderate to severe Crohn\u2019s disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Paul","family":"Rutgeerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy L.","family":"Keininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Fedorak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CDP870 Crohn\u2019s Disease Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,11]]},"reference":[{"key":"395_CR1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/gut.28.4.378","volume":"28","author":"BG Gazzard","year":"1987","unstructured":"Gazzard BG (1987) The quality of life in Crohn\u2019s disease. Gut 28:378\u2013381","journal-title":"Gut"},{"key":"395_CR2","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","volume":"16","author":"RD Cohen","year":"2002","unstructured":"Cohen RD (2002) The quality of life in patients with Crohn\u2019s disease. Aliment Pharmacol Ther 16:1603\u20131609","journal-title":"Aliment Pharmacol Ther"},{"key":"395_CR3","volume-title":"Quality of life: assessment and application. CMR Workshop","year":"1987","unstructured":"Walker SR, Rosser RM (eds) (1987) Quality of life: assessment and application. CMR Workshop. MTP Press, Lancaster, UK"},{"key":"395_CR4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0016-5085(90)91234-W","volume":"99","author":"JW Garrett","year":"1990","unstructured":"Garrett JW, Drossman DA (1990) Health status in IBD: biological and behavioral considerations. Gastroenterology 99:90\u201396","journal-title":"Gastroenterology"},{"key":"395_CR5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00006842-199111000-00010","volume":"53","author":"DA Drossman","year":"1991","unstructured":"Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL (1991) The rating form of IBD patient concern: a new measure of health status. Psychosom Med 53:701\u2013712","journal-title":"Psychosom Med"},{"key":"395_CR6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern FJn (1976) Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology 70:439\u2013444","journal-title":"Gastroenterology"},{"key":"395_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","volume":"106","author":"EJ Irvine","year":"1994","unstructured":"Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW (1994) Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn\u2019s Relapse Prevention Trial Study Group. Gastroenterology 106:287\u2013296","journal-title":"Gastroenterology"},{"key":"395_CR8","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","volume":"98","author":"BG Feagan","year":"2003","unstructured":"Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR (2003) The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 98:2232\u20132238","journal-title":"Am J Gastroenterol"},{"key":"395_CR9","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/j.1572-0241.2001.04681.x","volume":"96","author":"F Blondel-Kucharski","year":"2001","unstructured":"Blondel-Kucharski F, Chircop C, Marquis P, Cortot A, Baron F, Gendre JP, Colombel JF, Groupe d\u2019Etudes Therapeutique des Affections Inflammatoires Digestives (GETAID) (2001) Health-related quality of life in Crohn\u2019s disease; a prospective longitudinal study in 231 patients. Am J Gastroenterol 96:2915-2920","journal-title":"Am J Gastroenterol"},{"key":"395_CR10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2036.2006.02753.x","volume":"23","author":"C Canavan","year":"2006","unstructured":"Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF (2006) Long-term prognosis in Crohn\u2019s disease: factors that affect quality of life. Aliment Pharmacol Ther 23:377\u2013385","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. C","key":"395_CR11","doi-asserted-by":"crossref","first-page":"17C","DOI":"10.1155\/2000\/513130","volume":"14","author":"WJ Sandborn","year":"2000","unstructured":"Sandborn WJ (2000) Steroid-dependent Crohn\u2019s disease. Can J Gastroenterol 14(Suppl. C):17C\u201322C","journal-title":"Can J Gastroenterol"},{"key":"395_CR12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","volume":"15","author":"PJ Rutgeerts","year":"2001","unstructured":"Rutgeerts PJ (2001) Review article: the limitations of corticosteroid therapy in Crohn\u2019s disease. Aliment Pharmacol Ther 15:1515\u20131525","journal-title":"Aliment Pharmacol Ther"},{"key":"395_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00042737-200510000-00006","volume":"17","author":"T Bernklev","year":"2005","unstructured":"Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold O, Aadland E, Vatn M, Moum B (2005) Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5\u00a0years after initial diagnosis. Eur J Gastrenterol Hepatol 17:1037\u20131045","journal-title":"Eur J Gastrenterol Hepatol"},{"key":"395_CR14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/BF01538073","volume":"34","author":"DA Drossman","year":"1989","unstructured":"Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI (1989) Health-related quality of life in inflammatory bowel disease: Functional status and patient worries and concerns. Dig Dis Sci 34:1379\u20131386","journal-title":"Dig Dis Sci"},{"key":"395_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","volume":"40","author":"SJ Deventer van","year":"1997","unstructured":"van Deventer SJ (1997) Tumour necrosis factor and Crohn\u2019s disease. Gut 40:443\u2013448","journal-title":"Gut"},{"key":"395_CR16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial. ACCENT I Study Group. Lancet 359:1541\u20131549","journal-title":"Lancet"},{"key":"395_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00054725-200207000-00001","volume":"8","author":"GR Lichtenstein","year":"2002","unstructured":"Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T (2002) Infliximab improves quality of life in patients with Crohn\u2019s disease. Inflamm Bowel Dis 8:237\u2013243","journal-title":"Inflamm Bowel Dis"},{"key":"395_CR18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D\u2019Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 348:601\u2013608","journal-title":"N Engl J Med"},{"key":"395_CR19","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1046\/j.1440-1746.17.s1.1.x","volume":"17","author":"P Rutgeerts","year":"2002","unstructured":"Rutgeerts P (2002) A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 17:S176\u2013S185","journal-title":"J Gastroenterol Hepatol"},{"key":"395_CR20","doi-asserted-by":"crossref","unstructured":"Fossati G, Nesbitt A (2005) In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol. Poster presentation at American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course, Hawaii, October 28\u2013November 2, 2005 (Abstract 807)","DOI":"10.14309\/00000434-200509001-00807"},{"key":"395_CR21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","volume":"129","author":"S Schreiber","year":"2005","unstructured":"Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A, CDP870 Crohn\u2019s Disease Study Group (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. The CDP870 Crohn\u2019s Disease Study Group. Gastroenterology 129:807\u2013818","journal-title":"Gastroenterology"},{"key":"395_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med 357:228\u2013238","journal-title":"N Engl J Med"},{"key":"395_CR23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC et al (2007) Certolizumab pegol maintenance therapy for Crohn\u2019s disease. N Engl J Med 357:239\u2013250","journal-title":"N Engl J Med"},{"key":"395_CR24","first-page":"2946","volume":"44","author":"E Keystone","year":"2001","unstructured":"Keystone E, Choy EH, Kalden J, Klareskog L, Sany J, Smolen J (2001) CDP870, a novel, PEGylated, humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA). Arthritis Rheum 44:2946","journal-title":"Arthritis Rheum"},{"key":"395_CR25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","volume":"42","author":"EH Choy","year":"2002","unstructured":"Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 42:1133\u20131137","journal-title":"Rheumatology"},{"key":"395_CR26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","volume":"96","author":"GH Guyatt","year":"1989","unstructured":"Guyatt GH, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804\u2013810","journal-title":"Gastroenterology"},{"key":"395_CR27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0895-4356(89)90128-5","volume":"42","author":"GH Guyatt","year":"1989","unstructured":"Guyatt GH, Deyo RA, Carlson M, Levine MN, Mitchell A (1989) Responsiveness and validity in health status management: a clarification. J Clin Epidemiol 42:403\u2013408","journal-title":"J Clin Epidemiol"},{"key":"395_CR28","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00005176-199904001-00003","volume":"28","author":"EJ Irvine","year":"1999","unstructured":"Irvine EJ (1999) Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality of life instrument for adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 28:S23\u2013S27","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"395_CR29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00042737-200105000-00017","volume":"13","author":"F Casellas","year":"2001","unstructured":"Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR (2001) Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 13:567\u2013572","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4 Suppl 1","key":"395_CR30","first-page":"A510","volume":"132","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Hanauer SB, Lichtenstein GR, Sandborn WJ (2007) Superior efficacy of certolizumab pegol in early Crohn's disease is independent of CRP status. Gastroenterology 132(4 Suppl 1):A510\u2013A511 (Abstract T1298)","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"395_CR31","first-page":"A124","volume":"55","author":"B Feagan","year":"2006","unstructured":"Feagan B, Coteur G, Keininger DL, Schreiber S (2006) Sustained improvement in health-related quality of life following certolizumab pegol 400\u00a0mg every 4\u00a0weeks in patients with Crohn\u2019s disease: data from PRECiSE 2. Gut 55(Suppl 5):A124(Abstract MON-G-219)","journal-title":"Gut"},{"issue":"4 Suppl 1","key":"395_CR32","first-page":"A508","volume":"132","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Sandborn W, Rutgeerts P, Coteur G, Keininger DL, Feagan B (2007) Induction of health-related quality-of-life response and remission in Crohn\u2019s disease patients following subcutaneous treatment with certolizumab pegol 400\u00a0mg: data from PRECiSE 1. Gastroenterology 132(4 Suppl 1):A508(Abstract T1287)","journal-title":"Gastroenterology"},{"key":"395_CR33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","volume":"331","author":"GR Greenberg","year":"1994","unstructured":"Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T (1994) Oral budesonide for active Crohn's disease. N Engl J Med 331:836\u2013841","journal-title":"N Engl J Med"},{"key":"395_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"BG Feagan","year":"1995","unstructured":"Feagan BG, Rochon J, Fedorak RN et al (1995) Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332:292\u2013297","journal-title":"N Engl J Med"},{"key":"395_CR35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1365-2036.2002.01268.x","volume":"16","author":"EJ Balkom Schoon van","year":"2002","unstructured":"van Balkom Schoon EJ, Stockbr\u00fcgger RW et al (2002) Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn\u2019s disease. Ailment Pharmacol Ther 16:1101\u20131107","journal-title":"Ailment Pharmacol Ther"},{"key":"395_CR36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"S Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, for the Natalizumab Pan-European Study Group et al (2003) N Engl J Med 348:24\u201332","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"395_CR37","first-page":"A1","volume":"130","author":"S Schreiber","year":"2006","unstructured":"Schreiber S, Feagan B, Hanauer SB, Rutgeerts P, McColm JA, Sandborn WJ (2006) Safety and tolerability of subcutaneous certolizumab pegol in active Crohn\u2019s disease: results from two Phase III studies (PRECiSE program). Gastroenterology 130(Suppl 2):A1\u2013A912","journal-title":"Gastroenterology"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-007-0395-7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T06:44:20Z","timestamp":1684133060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-007-0395-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,11]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1007\/s00384-007-0395-7","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,11]]}}}